BioCentury | Apr 6, 2018
Clinical News

Conatus' emricasan misses in Phase IIb in liver transplant patients

...of F2-F5 or improvement in Ishak Fibrosis Score for patients with a baseline score of F6...
BioCentury | Apr 5, 2018
Clinical News

Conatus falls as emricasan misses in liver transplant patients

...of F2-F5 or improvement in Ishak Fibrosis Score for patients with a baseline score of F6...
BioCentury | Jul 3, 2000
Clinical News

MVA F6 tyrosinase: Began Phase I/II trial

...Bavarian Nordic Research Institute A/S (CSE:BNRI), Glostrup, Denmark Product: MVA F6 tyrosinase Business: Cancer Therapeutic category...
...Target: Tumor cells Description: Vaccine consisting of a patient's dendritic cells grown with the MVA F6...
BioCentury | Feb 22, 2000
Clinical News

MVA F6 HIV- Nef: Began Phase I/II study

...Bavarian Nordic Research Institute A/S (CSE:BNRI), Glostrup, Denmark Product: MVA F6 HIV- Nef Business: Infectious diseases...
...HIV infection/AIDS Status: BNRI will begin a 10-patient Phase I/II safety study of its MVA F6...
BioCentury | Feb 22, 2000
Finance

Eurobio plays mixed on NASDAQ

...on Tuesday after saying it would begin Phase I/II studies in Germany of a MVA F6...
BioCentury | Feb 15, 2000
Clinical News

Bavarian Nordic starts HIV Phase I/II

...Bavarian Nordic (CSE:BNRI) will start a 10-patient Phase I/II trial in Germany with an MVA F6...
Items per page:
1 - 6 of 6